FDA releases statement on CAR T cells in autoimmunity

The FDA has released a statement saying it will “carefully shepherd” studies to advance the development of chimeric antigen receptor T-cell therapies in autoimmune and rheumatic diseases.
“It is quite important and very welcome that the FDA has publicly published their perspective on these therapies in our space of autoimmune and rheumatic conditions,” Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, and RJ Fasenmyer chair of clinical immunology at the Cleveland